HISUN(SH:600267)2023-03-30 16:00Financial Performance - The company achieved a total revenue of 12.037 billion RMB in 2022, a decrease of 0.82% compared to 2021, with main business revenue at 11.709 billion RMB, down by 1.93 billion RMB[3]. - The net profit attributable to the parent company, excluding non-recurring gains and losses, was 313 million RMB, an increase of 1.03 billion RMB, or 48.81% year-on-year[5]. - The total operating revenue for the period is approximately ¥12.04 billion, a slight decrease from ¥12.14 billion in the previous year[23]. - The company reported a significant increase in revenue, achieving a total of 1.2 billion RMB for the fiscal year, representing a 15% year-over-year growth[115]. - The company aims for a consolidated revenue target of 13 billion yuan in 2023, representing an 8% year-on-year increase[101]. Profitability and Margins - The company achieved a net profit margin of 10%, reflecting a 2% improvement compared to the previous year[112]. - The net profit margin for the shareholders of the parent company is 40.68%[131]. - The company reported a 5% increase in gross margin, reaching 45% for the fiscal year[115]. Revenue Breakdown by Segment - The pharmaceutical manufacturing segment reported revenue of approximately 6.721 billion RMB, with a gross margin of 62.38%, reflecting a decrease in revenue of 3.61% year-on-year[7]. - The pharmaceutical commercial business revenue was approximately 4.915 billion RMB, with a gross margin of 14.25%, showing a slight decrease of 0.06% year-on-year[9]. - The company’s oncology drugs revenue was approximately 971 million RMB, with a gross margin of 74.23%, reflecting a year-on-year increase of 15.50%[10]. - The cardiovascular drugs segment generated approximately 1.734 billion RMB in revenue, with a gross margin of 66.52%, an increase of 26.76% year-on-year[10]. - The company experienced a 20.21% decrease in revenue from anti-infection drugs, totaling CNY 2,191,687,828.64, with a gross margin of 64.28%[51]. Research and Development - Research and development expenses amount to ¥428.69 million, representing 3.56% of total operating revenue[24]. - The R&D investment accounted for 3.67% of the company's total revenue, with a net asset ratio of 5.47%[62]. - The company has several key R&D projects in Phase I clinical trials, including HS236, HS301, and HS248, all targeting oncology[53]. - Research and development expenses increased by 18%, totaling 150 million CNY, focusing on innovative drug development[112]. - The company is accelerating the research and development of generic and innovative drugs, focusing on core therapeutic areas and exploring external collaboration opportunities[144]. Cash Flow and Liabilities - The company’s operating cash flow remained positive, and interest-bearing liabilities decreased from 6.388 billion RMB in 2021 to 4.873 billion RMB in 2022, a reduction of 1.515 billion RMB[5]. - The net cash flow from operating activities increased by 18.96% to approximately ¥2.07 billion compared to ¥1.74 billion in the previous year[25]. Strategic Initiatives - The company plans to enhance its product offerings and expand its market presence through strategic collaborations and innovation in drug development[2]. - The company is actively pursuing market expansion and product registration to enhance its market presence and sales revenue[50]. - The company plans to actively explore new retail channels and leverage e-commerce opportunities in response to internet healthcare policies[35]. - The company is exploring strategic acquisitions to enhance its product portfolio and market presence[112]. - A strategic acquisition of a biotech firm was completed, valued at 300 million RMB, aimed at enhancing R&D capabilities[123]. Employee and Governance - The total number of employees at the parent company is 3,008, while the total number of employees at major subsidiaries is 5,317, resulting in a combined total of 8,325 employees[125]. - The company has established a performance evaluation mechanism for senior management, with a compensation management system in place since 2020[147]. - The company maintains a governance structure that complies with relevant laws and regulations, ensuring effective checks and balances among shareholders, the board, and management[74]. Environmental and Social Responsibility - The company invested a total of 4.4873 million yuan in social responsibility initiatives during the reporting period[173]. - The company has committed to minimizing related party transactions and ensuring fairness in pricing and decision-making processes[179]. - The company has signed a soil pollution prevention responsibility agreement with the Fuyang District government on June 30, 2022[171]. - The company has implemented an environmental self-monitoring plan, with third-party testing confirming that all pollutant indicators meet discharge standards[168]. Shareholder Returns - The company distributed a cash dividend of 198,933,847.51 RMB, which represents 80.92% of the net profit attributable to ordinary shareholders in the consolidated financial statements[131]. - The total cash dividend amount, including share repurchase, is 395,713,613.17 RMB[131]. - The company plans to continue its cash dividend policy without adjustments, ensuring the protection of minority shareholders' rights[128].